Kager P A
Academisch Medisch Centrum, afd. Infectieziekten, Tropische Geneeskunde en Aids, Postbus 22.700, 1100 DE Amsterdam.
Ned Tijdschr Geneeskd. 2003 Feb 15;147(7):291-5.
Three new antimalarial drugs have recently been registered in the Netherlands: atovaquone-proguanil, artemether-lumefantrine and artemotil. These drugs are effective against parasites with multiple resistance. Atovaquone-proguanil and artemether-lumefantrine seem in practice to be equivalent for the treatment of non-severe Plasmodium falciparum infections for respectively persons of more than 11 kg and persons aged 12 years and older (35 kg). Artemotil (intramuscular injection) is registered for the treatment of severe malaria in children up to 17 years of age. Atovaquone-proguanil is also registered for prophylactic use in adults. The intravenous administration of quinine is preferable in the case of seriously ill patients. In patients with non-severe malaria for whom parenteral treatment is indicated, artemotil is a good alternative for quinine.
阿托伐醌-氯胍、蒿甲醚-本芴醇和蒿乙醚。这些药物对具有多重耐药性的寄生虫有效。实际上，阿托伐醌-氯胍和蒿甲醚-本芴醇对于治疗非重症恶性疟原虫感染似乎等效，分别适用于体重超过11公斤的人群以及12岁及以上（35公斤）的人群。蒿乙醚（肌肉注射）注册用于治疗17岁以下儿童的重症疟疾。阿托伐醌-氯胍也注册用于成人预防用药。对于重症患者，静脉注射奎宁更为可取。对于需要进行非重症疟疾肠外治疗的患者，蒿乙醚是奎宁的良好替代品。
